News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Elyse Hall Panjic, PharmD, BCOP

Articles by Elyse Hall Panjic, PharmD, BCOP

100 Non-Pharmacological Interventions for Managing Abemaciclib-Associated Adverse Events in Patients With Early/Advanced HR+/HER2– Breast Cancer: A US-Based Health Care Provider Survey

ByAlexandra Vitko,Pamela K Ginex,Kelli Thoele,Qinli Lily Ma,Astra Liepa,Wambui Gathirua-Mwangi,Elyse Hall Panjic, PharmD, BCOP,Engels Chou,Jodi L Taraba,Hilary Ellis,Charlotte Clewes,Joanna de Courcy,Hope S. Rugo, MD

April 15th 2025

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis

ByKevin H. Hall, PharmD, BCOP,Elyse Hall Panjic, PharmD, BCOP,Kelly Valla, PharmD, BCOP,Christopher R. Flowers, MD, MS,Jonathon B. Cohen, MD, MS

June 15th 2018

Here we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.

Latest Updated Articles

How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis
Published: June 15th 2018 | Updated:

Trending on CancerNetwork

Modifiable Risk Factors Suggest Potential for Improving Cancer Prevention

Barriers to CAR T-Cell Referral and Center Access in Multiple Myeloma

2026 Tandem Meetings: What’s the Latest Research in Multiple Myeloma?

Exploring The Impact of ADTs on Cardiac Risk in Prostate Cancer Treatment

Real World Outcomes of CAR T-Cell Therapy in Multiple Myeloma Including Older and Comorbid Patients